NEW YORK (GenomeWeb) – Due to the availability of new data, Medicare contractor Noridian said it will retire a recently issued draft local coverage determination in which it proposed to limit coverage for a number of biomarker tests to guide decisions about adjuvant chemotherapy in breast cancer patients (see pdf below).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.